It is the vaccine that could be a game-changer in Europe.
In a few weeks, the likely arrival of AstraZeneca / Oxford doses on the Old Continent should reduce the pressure on the governments of the Member States.
Both because of the expected volumes (up to 400 million doses) and the storage conditions of this vaccine, which are less restrictive than those of the Pfizer / BioNTech and Moderna vaccines.
The European Medicines Agency (EMA), which received an application for authorization for the British vaccine on Tuesday, said it would conduct a fast-track review and could render its decision on January 29 if the data communicated is sufficiently
"robust. and complete ”
.
The company has around twenty partners in fifteen countries to produce its doses.
From the green light from the EMA, deliveries to France of the first doses should take a few days, in particular the time to obtain the approval of the High Authority for Health.
The agreement with AstraZeneca and Oxford
This article is for subscribers only.
You have 75% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
I ENJOY IT
Already subscribed?
Log in
